SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
CARDIOGENESIS CORPORATION
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
14159K 10 5
---------------------------------------------
(CUSIP Number)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 8 Pages
<PAGE>
CUSIP No. 14159K 10 5 13G Page 2 of 8 Pages
- -------------------------------------------------------------------------------
1. Name of Reporting Person Guidant Corporation
S.S. or I.R.S. Identification
No. of Above Person
- -------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------
3. SEC Use Only
- -------------------------------------------------------------------------------
4. Citizenship or Place of Organization Indiana
- -------------------------------------------------------------------------------
5. Sole Voting Power 1,695,760
Number of
Shares --------------------------------------------------------------
Beneficially 6. Shared Voting Power 0
Owned by
Each --------------------------------------------------------------
Reporting 7. Sole Dispositive Power 1,695,760
Person
With --------------------------------------------------------------
8. Shared Dispositive Power 0
- -------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned
by Each Reporting Person 1,695,760
- -------------------------------------------------------------------------------
10. Check if the Aggregate Amount
in Row 9 Excludes Certain Shares [ ]
- -------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row 9 14.17%
- -------------------------------------------------------------------------------
12. Type of Reporting Person HC
- -------------------------------------------------------------------------------
<PAGE>
CUSIP No. 14159K 10 5 13G Page 3 of 8 Pages
- -------------------------------------------------------------------------------
1. Name of Reporting Person Advanced Cardiovascular
Systems, Inc.
S.S. or I.R.S. Identification
No. of Above Person
- -------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------
3. SEC Use Only
- -------------------------------------------------------------------------------
4. Citizenship or Place of Organization California
- -------------------------------------------------------------------------------
5. Sole Voting Power 1,695,760
Number of
Shares ------------------------------------------------------------
Beneficially 6. Shared Voting Power 0
Owned by
Each ------------------------------------------------------------
Reporting 7. Sole Dispositive Power 1,695,760
Person
With ------------------------------------------------------------
8. Shared Dispositive Power 0
- -------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned
by Each Reporting Person 1,695,760
- -------------------------------------------------------------------------------
10. Check if the Aggregate Amount
in Row 9 Excludes Certain Shares [ ]
- -------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row 9 14.17%
- -------------------------------------------------------------------------------
12. Type of Reporting Person CO
- -------------------------------------------------------------------------------
<PAGE>
CUSIP No. 14159K 10 5 13G Page 4 of 8 Pages
Item 1(a) Name of Issuer: CardioGenesis Corporation
--------------
Item 1(b) Address of Issuer's Principal Executive Offices:
-----------------------------------------------
540 Oakmead Parkway, Sunnyvale, California 94086
Item 2(a) Name of Person Filing: Guidant Corporation, an Indiana
---------------------
corporation ("Guidant"), on its behalf and on behalf of Advanced
Cardiovascular Systems, Inc., a California corporation and wholly
owned subsidiary of Guidant ("ACS").
Item 2(b) Address of Principal Business Office:
------------------------------------
3200 Lakeside Drive, Santa Clara, CA 95054-2807
Item 2(c) Citizenship: Guidant is a Delaware corporation
-----------
and ACS is a California corporation.
Item 2(d) Title of Class of Securities: Common Stock
----------------------------
Item 2(e) CUSIP Number: 14159K 10 5
------------
Item 3. If this statement is filed pursuant to Rule 13d-1(b) or
-------------------------------------------------------
13d-2(b), check whether the person filing is a:
----------------------------------------------
(a) [ ] Broker or Dealer registered under
section 15 of the Act
(b) [ ] Bank as defined in section 3(a)(6) of the
Act
(c) [ ] Insurance Company as defined in section
3(a)(19) of the Act
(d) [ ] Investment Company registered under
section 8 of the Investment Company Act
(e) [ ] Investment Adviser registered under
section 203 of the Investment Advisers Act
of 1940
(f) [ ] Employee Benefit Plan, Pension Fund which
is subject to the provisions of the
Employee Retirement Income Security Act of
1974 or Endowment Fund
(g) [X] Parent Holding Company, in accordance with
section 240.13d-1(b)(ii)(G) (Note: See
Item 7)
(h) [ ] Group, in accordance with section
240.13d-1(b)(1)(ii)(H)
<PAGE>
CUSIP No. 14159K 10 5 13G Page 5 of 8 Pages
Item 4. Ownership.
---------
(a) Amount Beneficially Owned:
-------------------------
ACS is the record holder of 1,695,760 shares of Common Stock and
may be deemed to beneficially own 1,695,760 shares of Common Stock. Guidant owns
100% of the outstanding stock of ACS and may be deemed to beneficially own
1,695,760 shares of Common Stock.
(b) Percent of Class:
----------------
ACS 14.17%
(c) Number of shares as to which such person has:
--------------------------------------------
(i) sole power to vote or to direct the vote; (ii) shared power
to vote or direct the vote; (iii) sole power to dispose or to direct the
disposition of; or (iv) shared power to dispose or to direct the disposition of:
ACS may be deemed to have sole power to vote and dispose of
1,695,760 shares of Common Stock. Guidant, as the parent company of ACS, may be
deemed to have sole power to vote and dispose of 1,695,760 shares of Common
Stock.
Item 5. Ownership of Five Percent or Less of a Class.
--------------------------------------------
Not Applicable.
Item 6. Ownership of More Than Five Percent on Behalf of
------------------------------------------------
Another Person.
--------------
Not Applicable.
Item 7. Identification and Classification of the
----------------------------------------
Subsidiary Which Acquired the Security Being
--------------------------------------------
Reported on by the Parent Holding Company.
-----------------------------------------
ACS is a wholly owned subsidiary of Guidant. This Schedule 13G is
being filed on behalf of ACS and Guidant.
Item 8. Identification and Classification of Members of
-----------------------------------------------
the Group.
---------
Not Applicable.
Item 9. Notice of Dissolution of Group.
------------------------------
Not Applicable.
<PAGE>
CUSIP No. 14159K 10 5 13G Page 6 of 8 Pages
Item 10. Certification.
-------------
By signing below, I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purposes or effect.
<PAGE>
CUSIP No. 14159K 10 5 13G Page 7 of 8 Pages
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 13, 1997.
ADVANCED CARDIOVASCULAR SYSTEMS, INC.
By /s/ Ginger Howard
------------------------------------------
Name Ginger Howard
----------------------------------------
Title President and CEO
---------------------------------------
GUIDANT CORPORATION
By /s/ Ginger Howard
------------------------------------------
Name Ginger Howard
----------------------------------------
Title Vice President
---------------------------------------
<PAGE>
CUSIP No. 14159K 10 5 13G Page 8 of 8 Pages
EXHIBIT A
---------
Joint Filing Agreement
----------------------
The undersigned hereby agree that the statement on Schedule 13G with
respect to the Common Stock of CardioGenesis Corporation dated February 13,
1997, is, and any amendments thereto signed by each of the undersigned shall be,
filed on behalf of each of us pursuant to and in accordance with the provisions
of Rule 13(d)-1(f) under the Securities Exchange Act of 1934.
Dated: February 13, 1997.
ADVANCED CARDIOVASCULAR SYSTEMS, INC.
By /s/ Ginger Howard
------------------------------------------
Name Ginger Howard
----------------------------------------
Title President and CEO
---------------------------------------
GUIDANT CORPORATION
By /s/ Ginger Howard
------------------------------------------
Name Ginger Howard
----------------------------------------
Title Vice President
---------------------------------------
